

4. Piganeau G, Eyre-Walker A (2004) A reanalysis of the indirect evidence for recombination in human mitochondrial DNA. *Heredity* 92:282–288
5. Wallace DC (1994) Mitochondrial DNA sequence variation in human evolution and disease. *Proc Natl Acad Sci USA* 91: 8739–8746
6. Macaulay V, Richards M, Hickey E, Vega E, Cruciani F, Guida V, Scozzari R, Bonne-Tamir B, Sykes B, Torroni A (1999) The emerging tree of West Eurasian mtDNAs: a synthesis of control-region sequences and RFLPs. *Am J Hum Genet* 64:232–249
7. Herrnstadt C, Elson JL, Fahy E, Preston G, Turnbull DM, Anderson S, Ghosh SS, Olefsky J, Beal MF, Davis RE, et al (2002) Reduced median network analysis of complete mtDNA coding region sequences for the major African, Asian, and European haplogroups. *Am J Hum Genet* 70:1152–1171
8. Finnila S, Lehtonen MS, Majamaa K (2001) Phylogenetic network for European mtDNA. *Am J Hum Genet* 68:1475–8144
9. Moilanen JS, Majamaa K (2003) Phylogenetic network and physicochemical properties of nonsynonymous mutations in the protein-coding genes of human mitochondrial DNA. *Mol Biol Evol* 20:1195–1210
10. Mohlke KL, Jackson AU, Scott LJ, Peck EC, Suh YD, Chines PS, Watanabe RM, Buchanan TA, Conneely KN, Erdos MR, et al (2005) Mitochondrial polymorphisms and susceptibility to type 2 diabetes-related traits in Finns. *Hum Genet* 118:245–254
11. Elson JL, Herrnstadt C, Preston G, Thal L, Morris CM, Edwardson JA, Beal MF, Turnbull DM, Howell N (2006) Does the mitochondrial genome play a role in the etiology of Alzheimer's disease? *Hum Genet* 119:241–254
12. van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Jonathan L. Haines, William C. Koller, Lyons K, et al (2003) Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. *Am J Hum Genet* 72:804–811
13. van der Walt JM, Dementieva YA, Martin ER, Scott WK, Nicodemus KK, Kroner CC, Welsh-Bohmer KA, Saunders AM, Roses AD, Small GW, et al (2004) Analysis of European mitochondrial haplogroups with Alzheimer disease risk. *Neurosci Lett* 365:28–32
14. Ruiz-Pesini E, Mishmar D, Brandon M, Procaccio V, Wallace DC (2004) Effects of purifying and adaptive selection on regional variation in human mtDNA. *Science* 303:223–226
15. Lertrit P, Kapsa RM, Jean-Francois MJ, Thyagarajan D, Noer AS, Marzuki S, Byrne E (1994) Mitochondrial DNA polymorphism in disease: a possible contributor to respiratory dysfunction. *Hum Mol Genet* 3:1973–1981
16. Niemi AK, Moilanen JS, Tanaka M, Hervonen A, Hurme M, Lehtimäki T, Arai Y, Hirose N, Majamaa K (2005) A combination of three common inherited mitochondrial DNA polymorphisms promotes longevity in Finnish and Japanese subjects. *Eur J Hum Genet* 13:166–170
17. Mackey DA, Oostra RJ, Rosenberg T, Nikoskelainen E, Bronte-Stewart J, Poulton J, Harding AE, Govan G, Bolhuis PA, Norby S (1996) Primary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathy. *Am J Hum Genet* 59:481–485
18. Torroni A, Petrozzi M, D'Urbano L, Sellitto D, Zeviani M, Carrara F, Carducci C, Leuzzi V, Carelli V, Barboni P, et al (1997) Haplotype and phylogenetic analyses suggest that one European-specific mtDNA background plays a role in the expression of Leber hereditary optic neuropathy by increasing the penetrance of the primary mutations 11778 and 14484. *Am J Hum Genet* 60:1107–1121
19. Man PY, Howell N, Mackey DA, Norby S, Rosenberg T, Turnbull DM, Chinnery PF (2004) Mitochondrial DNA haplogroup distribution within Leber hereditary optic neuropathy pedigrees. *J Med Genet* 41:e41
20. Carelli V, Achilli A, Valentino ML, Rengo C, Semino O, Pala M, Olivieri A, Mattiazzi M, Pallotti F, Carrara F, et al (2006) Haplogroup effects and recombination of mitochondrial DNA: novel clues from the analysis of Leber hereditary optic neuropathy pedigrees. *Am J Hum Genet* 78:564–574
21. Torroni A, Campos Y, Rengo C, Sellitto D, Achilli A, Magri C, Semino O, Garcia A, Jara P, Arenas J, et al (2003). Mitochondrial DNA haplogroups do not play a role in the variable phenotypic presentation of the A3243G mutation. *Am J Hum Genet* 72:1005–1012
22. Houshmand M, Sharifpanah F, Tabasi A, Sanati MH, Vakilian M, Lavasani SH, Joughedoust S (2004) Leber's hereditary optic neuropathy: the spectrum of mitochondrial DNA mutations in Iranian patients. *Ann N Y Acad Sci* 1011:345–349

From the Mitochondrial Research Group (J.L.E.; P.F.C.) and Institute of Human Genetics (P.F.C.), The University of Newcastle upon Tyne, Newcastle upon Tyne; Department of Neurology, University of Turku, Turku, Finland (K.M.); and MIGENIX Corporation, San Diego (N.H.)

Address for correspondence and reprints: Dr. Joanna L. Elson, Department of Neurology, The Medical School, Newcastle University, Newcastle-upon-Tyne NE2 4HH, United Kingdom. E-mail: J.L.elson@ncl.ac.uk

Am. J. Hum. Genet. 2007;80:378. © 2006 by The American Society of Human Genetics. All rights reserved.
0002-9297/2007/8002-0019\$15.00

Reply to Elson et al.

To the Editor:

We recently reported an association study of common mtDNA variation with risk of type 2 diabetes and metabolic traits.¹ We tested a simple model with few assumptions: that each common DNA sequence variant might, irrespective of its place in the mtDNA phylogeny, be associated with disease. Although Elson et al.² agree that our “approach will detect a robust disease association,” they have three concerns: (i) that the catalogue of common variation is not representative of European mtDNAs, (ii) that our tag SNPs do not adequately capture mtDNA haplogroups, and (iii) that we failed to consider epistasis. We believe these views to be misinterpretations of our article, as well as a reflection of a difference in philosophy on limiting association studies on the basis of prior assumptions.

We developed a catalogue of common mtDNA variation on the basis of publicly available mtDNA sequences. Perhaps we were insufficiently precise in the text, as Elson et al. misinterpret which samples were used. In the European alignment, we studied 928 mtDNAs of only European origin: 429 from MitoKor, 240 from the Armed Forces Institute of Pathology, 192 from Finland, and 67 from smaller studies. (Although we used 536 MitoKor sequences for

worldwide alignment, only 429 were included in subsequent analyses.)

Elson et al. criticize our inclusion of m.13105, which they describe as “most often associated with African lineages.”² Although it is true that m.13105 is more common in African samples, it is present at a frequency of 1.2% in the 6,000 European samples we studied and at 3% in HapMap CEU samples.³ We are perplexed as to why Elson et al. write that this variant “should not have been used in the analysis,”² because it is in fact present in our samples and could, in principle, influence traits. We do agree that our catalogue is only as representative as the public database used to create it. We note that association testing performed using tags from 928 complete sequences is dramatically more complete than current standards.

Second, Elson et al. assert that our tag SNP and testing strategy captures only a small fraction of European mtDNA phylogeny.^{2,4} As shown in table 4 of our article,¹ the common variants identified, as well as nine canonical European haplogroups, are well predicted by the tag SNPs and specified haplotype tests. Perhaps Elson et al. do not consider the specified haplotype tests that we performed, as, in their example (shown in red in their fig. 1), although no single SNP captures m.5046 of haplogroup W, a specified haplotype test (that we did perform) does. We do not understand why Elson et al. argue that our strategy might lead to “spurious associations,”² nor do Elson et al. provide an explanation of this claim.

Third, we agree that interaction among variants may alter risk, which is why we performed pairwise tests involving all SNPs with nominal $P < .1$ in the initial screen.^{1(p57)} Marchini et al. showed this approach to be well powered.^{5,6}

Finally, Elson et al. argue that limiting association tests to the classical phylogeny and variants with “direct functional consequences” will “increase the power of the study.”² We agree—under the model in which their assumptions are correct. Of course, under the model in which some causal variants are not restricted to a classical haplogroup or might not yet be suspected as contributing to disease, power will decrease under the advocated approach.

RICHA SAXENA, PAUL I. W. DE BAKKER, LEIF C. GROOP,
MARK J. DALY, AND DAVID ALTSHULER

References

1. Saxena R, de Bakker PIW, Singer K, Mootha VK, Burt N, Hirschhorn JN, Gaudet D, Isomaa B, Daly MJ, Groop L, et al (2006) Comprehensive association testing of common mitochondrial DNA variation in metabolic disease. *Am J Hum Genet* 79:54–61
2. Elson JL, Majamaa K, Howell N, Chinnery PF (2007) Associating mitochondrial DNA variation with complex traits. *Am J Hum Genet* 80:378–382 (in this issue)
3. The International HapMap Consortium (2005) A haplotype map of the human genome. *Nature* 437:1299–1320
4. Herrnstadt C, Elson JL, Fahy E, Preston G, Turnbull DM, Anderson C, Ghosh SS, Olefsky JM, Beal MF, Davis RE, et al (2002) Reduced-median-network analysis of complete mitochondrial

DNA coding-region sequences for the major African, Asian, and European haplogroups. *Am J Hum Genet* 70:1152–1171

5. Marchini J, Donnelly P, Cardon LR (2005) Genome-wide strategies for detecting multiple loci that influence complex diseases. *Nat Genet* 37:413–417
6. Daly MJ, Altshuler, D (2005) Partners in crime. *Nat Genet* 37:337–338

From the Center for Human Genetic Research, Massachusetts General Hospital (R.S.; P.I.W.d.B.; M.J.D.; D.A.), and Program in Medical and Population Genetics, Broad Institute of Harvard and MIT (R.S.; P.I.W.d.B.; M.J.D.; D.A.), Boston; and Department of Clinical Sciences—Diabetes and Endocrinology at University Hospital MAS, Lund University, Lund, Sweden (L.C.G.)

Address for correspondence and reprints: Dr. Richa Saxena, Department of Molecular Biology, Massachusetts General Hospital, Simches Research Building, 175 Cambridge Street, CPZN-6818, Boston, MA 02114. E-mail: saxena@molbio.mgh.harvard.edu

Am. J. Hum. Genet. 2007;80:378. © 2007 by The American Society of Human Genetics. All rights reserved.

0002-9297/2007/8002-0020\$15.00

Genetic Association Analysis of *RHOB* and *TXNDC3* in Osteoarthritis

To the Editor:

In the May 2006 issue of *The American Journal of Human Genetics*, Mahr et al.¹ reported an association with osteoarthritis (OA [MIM 165720]) for a SNP (*rs49846015*) located immediately 5' of the coding region of *RHOB* (on chromosome 2p24.1 [MIM 165370]) and for a SNP (*rs4720262*) located immediately 5' of the coding region of *TXNDC3* (on chromosome 7p14.1 [MIM 607421]). *RHOB* codes for a GTP-binding protein whereas *TXNDC3* codes for a thioredoxin protein. The association study by Mahr et al. was performed with 171 patients with OA (74% females) who had undergone joint-replacement surgery (68% knee and 32% hip) and with 182 healthy control subjects (66% females), all of European white ethnicity. Possession of a copy of the G allele of *rs49846015* was an OA risk factor ($P = .0007$), as was possession of the T allele of *rs4720262* ($P = .0007$).

To assess the robustness of these associations, we have genotyped the SNPs in our collection of >1,500 case patients with OA (mean age 65 years; age range 56–85 years) and >700 age-matched control subjects (mean age 69 years; age range 55–89 years). As in the study by Mahr et al.,¹ our case patients were ascertained by joint-replacement surgery (hip, knee, or hip and knee) due to severe end-stage OA. Our control subjects had no signs or symptoms of arthritis or joint disease (pain, swelling, tenderness, or restriction of movement). All case patients and control subjects were individuals from the United Kingdom who are of white European ethnicity. Further details about the ascertainment of our case patients and control subjects have been published elsewhere.² Ethical approval for our study was obtained from the appropriate ethics